CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
IRADIMED (NASDAQ: IRMD) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will release its Q1 2025 financial results before market opening on Monday, May 5, 2025. Management will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link. Upon registration, they will receive a dial-in number, unique pin, and instructions. The call will also be available via live webcast on the company's investor relations website, with a recording made available afterward.
IRADIMED (NASDAQ: IRMD) ha annunciato la pubblicazione dei risultati finanziari del primo trimestre 2025 e il calendario della conference call. La società renderà noti i risultati del Q1 2025 prima dell'apertura dei mercati, lunedì 5 maggio 2025. La direzione terrà una conference call alle 9:00 AM ora Eastern dello stesso giorno per discutere i risultati e rispondere alle domande.
Gli interessati possono registrarsi alla conference call tramite un link fornito. Dopo la registrazione, riceveranno un numero per la chiamata, un pin univoco e le istruzioni. La chiamata sarà inoltre disponibile in diretta streaming sul sito web delle relazioni con gli investitori della società, con la registrazione disponibile successivamente.
IRADIMED (NASDAQ: IRMD) ha anunciado la publicación de sus resultados financieros del primer trimestre de 2025 y el calendario de la llamada de conferencia. La empresa dará a conocer los resultados del Q1 2025 antes de la apertura del mercado el lunes 5 de mayo de 2025. La dirección realizará una llamada de conferencia a las 9:00 a.m. hora del Este el mismo día para discutir los resultados y responder preguntas.
Los interesados pueden registrarse para la llamada de conferencia a través de un enlace proporcionado. Tras registrarse, recibirán un número de marcación, un PIN único y las instrucciones. La llamada también estará disponible en una transmisión en vivo en el sitio web de relaciones con inversores de la empresa, con una grabación disponible posteriormente.
IRADIMED (NASDAQ: IRMD)는 2025년 1분기 재무 실적 발표 및 컨퍼런스 콜 일정을 발표했습니다. 회사는 2025년 5월 5일 월요일 시장 개장 전 2025년 1분기 실적을 공개할 예정입니다. 경영진은 같은 날 동부 표준시 오전 9시에 컨퍼런스 콜을 개최하여 실적을 논의하고 질문에 답변할 예정입니다.
참가를 원하는 분들은 제공된 링크를 통해 컨퍼런스 콜에 등록할 수 있습니다. 등록 후에는 전화 접속 번호, 고유 PIN 및 안내 사항을 받게 됩니다. 콜은 회사 투자자 관계 웹사이트에서 라이브 웹캐스트로도 제공되며, 이후 녹화본도 이용할 수 있습니다.
IRADIMED (NASDAQ : IRMD) a annoncé la publication prochaine de ses résultats financiers du premier trimestre 2025 ainsi que le calendrier de la conférence téléphonique. La société publiera ses résultats du T1 2025 avant l’ouverture des marchés, le lundi 5 mai 2025. La direction animera une conférence téléphonique à 9h00, heure de l’Est le même jour pour discuter des résultats et répondre aux questions.
Les participants intéressés peuvent s’inscrire à la conférence téléphonique via un lien fourni. Après inscription, ils recevront un numéro d’appel, un code PIN unique et des instructions. La conférence sera également disponible en webcast en direct sur le site des relations investisseurs de la société, avec un enregistrement accessible par la suite.
IRADIMED (NASDAQ: IRMD) hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 sowie den Zeitplan für die Telefonkonferenz angekündigt. Das Unternehmen wird die Finanzergebnisse für Q1 2025 vor Markteröffnung am Montag, den 5. Mai 2025 veröffentlichen. Das Management wird am selben Tag um 9:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Fragen zu beantworten.
Interessierte Teilnehmer können sich über einen bereitgestellten Link für die Telefonkonferenz anmelden. Nach der Registrierung erhalten sie eine Einwahlnummer, eine individuelle PIN und Anweisungen. Die Telefonkonferenz wird außerdem live per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer anschließenden Aufzeichnung.
- None.
- None.
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows:
IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adff
Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRMD release its Q1 2025 earnings?
How can investors join IRMD's Q1 2025 earnings call?
What time is IRADIMED's Q1 2025 earnings call?
Will IRMD's Q1 2025 earnings call be recorded?
